Welcome to our dedicated page for Mind Medicine news (Ticker: MNMD), a resource for investors and traders seeking the latest updates and insights on Mind Medicine stock.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) is a late-stage clinical biopharmaceutical company developing novel product candidates to treat brain health disorders. Its news flow, as reflected in recent press releases and SEC filings, centers on clinical trial progress, scientific publications, financing activities and investor outreach related to its pipeline.
Investors following MNMD news can track updates on MM120, MindMed’s proprietary, pharmaceutically optimized form of lysergide D-tartrate (LSD), which the company is developing for generalized anxiety disorder and major depressive disorder. Recent announcements have highlighted Phase 3 studies of MM120 Orally Disintegrating Tablet (ODT) in GAD and MDD, as well as the publication of a Phase 2b GAD trial in the Journal of the American Medical Association (JAMA). MindMed also issues news on MM402, its proprietary form of R(−)-MDMA being developed for core symptoms of autism spectrum disorder.
MindMed’s news releases frequently cover financial results, underwritten public offerings of common shares, and the intended use of proceeds to fund research and development and general corporate purposes. The company also announces participation in major healthcare and investor conferences, such as events hosted by J.P. Morgan, Stifel, Jefferies, Evercore and Piper Sandler, and provides details on investor webcasts and corporate presentations.
This MNMD news page aggregates these company-issued updates so readers can review clinical milestones, capital markets transactions, and corporate communications in one place. Regularly reviewing this information can help market participants understand how MindMed reports on the advancement of its brain health pipeline and its interactions with the investment community.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced that CEO Robert Barrow will present at the H.C. Wainwright 23rd Annual Global Investment Conference from September 13-15, 2021. The company is focused on developing psychedelic-inspired therapies aimed at treating addiction and mental health issues. Management will also engage in one-on-one meetings with institutional investors during the event. A video webcast of the presentation will be available on-demand starting September 13, 2021, at 7:00 AM ET on MindMed's website.
On September 9, 2021, Mind Medicine (MindMed) announced that its Chief Medical Officer, Dr. Daniel R. Karlin, will co-chair the 8th annual Mobile in Clinical Trials Conference virtually on September 27, 2021. The conference aims to enhance the integration of digital technologies in clinical research. Dr. Karlin emphasized the importance of safety, stating that although they preferred in-person interaction, virtual formats can still facilitate knowledge exchange. MindMed is focused on developing psychedelic-inspired therapies for addiction and mental illness, with a diverse pipeline including psilocybin and MDMA.
MindMed (NASDAQ: MNMD) has partnered with BioXcel Therapeutics to publish an international patent application for a system that detects and prevents agitation in predisposed patients. The method utilizes continuous monitoring of physiological and behavioral signals to predict agitation episodes, allowing for early intervention by caregivers. This collaboration aims to enhance patient care and reduce emergency interventions associated with agitation symptoms, ultimately improving outcomes for individuals suffering from neurological and psychiatric conditions.
On August 24, 2021, Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) announced a collaboration with Forian Inc. (NASDAQ: FORA) to enhance personalized psychiatry for treating anxiety disorders through real-world evidence (RWE) data. This partnership aims to leverage real-world healthcare data to develop precise treatments by understanding individual physiological and environmental factors. MindMed focuses on psychedelic-inspired therapies, with a drug pipeline targeting mental illness and addiction. The initiative underscores the need for tailored mental health solutions amidst the ongoing impacts of the global pandemic.
Mind Medicine (MindMed) Inc. (NASDAQ: MNMD) has joined the Critical Path Institute's Patient-Reported Outcome (PRO) Consortium to enhance medical innovation and regulatory science. This collaboration aims to develop clinical outcome assessments (COAs) for clinical trials. According to Chief Medical Officer Daniel Karlin, the partnership will leverage real-world data to improve clinical evaluation and precision medicine. The PRO consortium supports patient-focused drug development, reinforcing MindMed's commitment to advancing psychedelic-inspired therapies for mental health issues.
MindMed (Nasdaq: MNMD) reported its Q2 2021 financial results, revealing total assets of $194 million as of June 30, including $157 million in cash. The company incurred a net loss of $36 million for the quarter, with $12 million used in operating activities. On the business front, MindMed launched Project Angie for pain treatment with psychedelics and partnered with Nextage Therapeutics to develop a brain-targeting delivery system. Upcoming earnings call is scheduled for August 16, 2021.
MindMed (NASDAQ: MNMD) has appointed Dr. Robert H. Dworkin to its Scientific Advisory Board, enhancing its expertise in pain management as it develops psychedelic-inspired therapies. Dr. Dworkin, a professor at the University of Rochester, brings over 35 years of clinical research experience in pain. His addition is expected to guide MindMed in clinical trials, focusing on leveraging psychedelics as innovative pain treatments. CEO Robert Barrow stated that Dr. Dworkin's experience will be invaluable in advancing MindMed's portfolio of chemical assets for pain management.
MindMed (NASDAQ: MNMD) has announced its participation in the Digital Medicine Society's Digital Health Measurement Collaborative Community (DATAcc), aimed at developing best practices for digital health measurement. The initiative includes leaders from government, non-profit, and private sectors, including the FDA. MindMed's Chief Medical Officer, Dan Karlin, emphasized the importance of real-world data in understanding mental health conditions. The collaborative will focus on areas such as data governance and digital inclusion, striving to enhance health outcomes and equity.
MindMed (NASDAQ: MNMD), a leading biotech firm focused on psychedelic-inspired therapies, announced that CEO Robert Barrow will host a roundtable at Cowen's Psychedelics & Novel Mechanisms in Neuropsychiatry Virtual Summit on July 13, 2021, from 4:15-5:00 PM ET. A live audio webcast will be accessible in the "Investors" section of MindMed's website, with a replay available for 30 days. MindMed is committed to developing innovative medications for addiction and mental health disorders using substances like psilocybin and LSD.
MindMed (NASDAQ: MNMD) announced a partnership with Datavant to utilize its data-linking technology for clinical trials. This will enhance MindMed's ability to connect its clinical data to external sources, improving insights into psychiatric and substance use disorders. The collaboration aims to create detailed datasets to refine clinical planning and commercialization. This initiative supports MindMed's goal of developing psychedelic-inspired therapies, potentially transforming mental health treatment.